Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis
Conditions
Brief summary
This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with treatment (advanced). Systemic mastocytosis is a disease in which too many mast cells (a type of immune system cell) are found throughout the body. Mast cells give off chemicals such as histamine that can cause flushing (a hot, red face), itching, abdominal cramps, muscle pain, nausea, vomiting, diarrhea, low blood pressure, and shock. Ibrutinib may stop the growth of mast cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVE: Evaluate the response rate to ibrutinib in patients with advanced systemic mastocytosis (SM) (aggressive systemic mastocytosis \[ASM\] or mast cell leukemia \[MCL\], or SM-associated hematologic non-mast cell disorder \[AHNMD\]) by the end of 6 cycles (6 months). SECONDARY OBJECTIVES: * Evaluate the tolerability and safety profile of ibrutinib in patients with advanced SM. * Evaluate the pharmacokinetic (PK) profile of ibrutinib in a subset of patients with advanced SM. * Evaluate changes in histopathology (blood and bone marrow) of patients with advanced SM in response to ibrutinib therapy. * Evaluate changes in mastocytosis related symptom scores and quality-of-life (QOL) using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF). * Evaluate the duration of response (DoR) and time to response (TTR). * Evaluate progression-free survival (PFS) and overall survival. OUTLINE: Patients receive ibrutinib orally (PO) once daily (QD) on days 1 to 28. Treatment repeats every 28 days for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving an unconfirmed or confirmed clinical improvement (CI), partial response (PR), or complete response (CR) by the end of course 6 will be permitted to continue maintenance courses of ibrutinib on an ongoing basis until loss of response/progressive disease, or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then every 6 months thereafter.
Interventions
DRUGIbrutinib
Given orally in 28-day cycles
Sponsors
National Cancer Institute (NCI)
Jason Robert Gotlib
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of systemic mastocytosis per 2008 World Health Organization (WHO) criteria. Those with advanced systemic mastocytosis (ASM); mast cell leukemia (MCL); or systemic mastocytosis-associated hematological clonal non-mast cell lineage disease (SM-AHNMD) required to have at least 1 organ damage finding * Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN); if considered related to ASM/MCL ≤ 5 x ULN * Estimated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault) * Total bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin); if considered related to ASM/MCL ≤ 3 x ULN * Female subjects must be of non-reproductive potential, or if of childbearing potential must have a negative serum pregnancy test upon study entry * Must agree to use highly effective methods of birth control * Written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 * Life expectancy \> 12 weeks
Exclusion criteria
* Received any investigational agent, chemotherapy, interferon-alpha, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to day 1; or monoclonal antibody ≤ 6 weeks prior to first administration of study treatment (patients with an AHNMD with progressive leukocytosis who require control of their counts are permitted to receive hydroxyurea) * Diagnosis of AHNMD requiring immediate cytoreductive therapy or targeted drugs (eg, acute myeloid leukemia \[AML\]) * History of other malignancies, except: * Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug, and at low risk for recurrence * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease * Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration \[\> 14 days\] of \> 10 mg/day of prednisone) within 28 days of the first dose of study drug * Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug * Systemic treatment for infection completed ≤ 14 days before the first dose of study drug * Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade 0 or 1, or to the levels dictated in the inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | Up to 6 months | Overall response rate (ORR) is reported as the sum of the rates of participants achieving complete remission (CR), partial remission (PR), & clinical improvement (CI). A clinical response is a response with duration of ≥ 12 weeks. CR is defined as all 4 criteria: * No presence of compact neoplastic mast cell aggregates * Serum tryptase level \< 20 ng/mL * Peripheral blood count remission defined as absolute neutrophil count (ANC) ≥1 x 10e9/L + normal differential, Hb ≥11 g/dL, & platelet count ≥100x10e9/L * Complete resolution of palpable hepatosplenomegaly & all biopsy-proven or suspected SM-related organ damage PR is defined as all 3 criteria with response duration ≥12 weeks, that is not CR or progressive disease: * ≥ 50% reduction in neoplastic mast cells * Serum tryptase level reduced ≥50% * Resolution of 1+ biopsy-proven or suspected systemic mastocytosis (SM)-related organ damage findings CI is defined as any improvement in any of the above measures. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ibrutinib Pharmacokinetics (PK) | 28 days | Plasma concentration-time profiles for each subject and mean plasma concentration-time profiles for each dose level will be plotted, plasma concentration data for ibrutinib at each time point will be summarized by descriptive statistics, and PK parameters such as maximum concentration (Cmax), minimum concentration, time at which the Cmax is reached, and area under the curve will be summarized with mean, geometric mean, medium, minimum, maximum, standard deviation, and coefficient of variation. |
| Change of Mast Cell Burden | 2 years | The change in the number of neoplastic mast cells in tissues (blood and/or bone marrow), ie, a measure of mast cell burden, will be assessed by immunophenotyping and/or immunohistochemistry (depending on patient and disease specifics) using mast cell markers, eg, CD25, CD30, CD117, tryptase, reticulin, Wright-Giemsa staining, and/or hematoxylin-eosin staining, in peripheral blood smears or bone marrow samples. For each participant, the data are used to collectively determine a single assessment for the number of mast cells present at baseline and after treatment. The outcome is reported as the median change in that level of mast cells, with full range, from baseline up to 2 years. |
| Serum Tryptase Levels | 2 years | Serum tryptase level is a surrogate marker for the desired histopathologic response, ie, reduction in mast cell burden. Serum tryptase levels are reported as the median of the percent reduction, with full range, from baseline up to 2 years. |
| Total Symptom Score (TSS) | 30 days | The totality of systemic mastocytosis was assessed by the total symptom score as measured by a Myeloproliferative Neoplasm Symptom Assessment Form modified for mast cell disorders \[MPN-SAF (MCD)\], and reported as the change in median score with standard deviation at baseline and 30 days. The MPN-SAF is a single, 27-question questionnaire that scores the following general measures on a scale of 0 (best) to 10 (worst): fatigue levels, effects of fatigue, satiety, pain, activity, concentration, dizziness, sleep, mood, anxiety, sexual function, itching, flushing, fever, weight loss, respiratory functions, diarrhea, lesions, and allergic reactions (some of these general terms may describe more than 1 assessment). The score on the MPN-SAF is the sum total of all 27 scores, and the range of scores is from a minimum of 0 (best; symptoms for all assessment absent) to a maximum of 270 (worst; score of 10 on all assessments). |
| Number of Participants With Adverse Events | 30 days | Adverse events will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, and reported as the number and percentage of participants having any adverse event; by each grade of adverse event; and by affected body systems. |
| Duration of Response (DoR) | 2 years | Duration of response (DoR) was assessed through 2 years of treatment, and reported as the median with standard deviation, with response duration censored at last response assessment in the event of death or progression not documented. |
| Time-to-Response (TTR) | 2 years | Time-to-response (TTR) was assessed through 2 years of treatment, and reported as the median with standard deviation, censored at last response assessment in the event of death or progression not documented. |
| Progression-free Survival (PFS) | 2 years | Participants were assessed for progression-free survival (PFS) from the start of treatment through 2 years of treatment. The outcome is reported as the number of participants who were alive without disease progression after 2 years of treatment. |
| Overall Survival (OS) | 26 months | Overall survival (OS) was assessed through 2 years of treatment, and recorded as the time from the start of treatment to either progression or death, with values censored at the last response assessment if the participant did not progress or die during that period. OS is reported as reported as the median with standard deviation. |
| Change in Quality of Life (QoL) | 30 days | The quality of life (QoL) component of the Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF) modified for mast cell symptoms, a scale of life quality ranking from 0 (best) to 10 (worst), was assessed at baseline and after 1 cycle of ibrutinib treatment (30 days), and reported as the median change in score with standard deviation. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ibrutinib 420 mg/Day Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
Ibrutinib: Given orally | 3 |
| Ibrutinib 560 mg/Day Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles
Ibrutinib: Given orally | 1 |
| Total | 4 |
Baseline characteristics
| Characteristic | Ibrutinib 420 mg/Day | Ibrutinib 560 mg/Day | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 1 Participants | 2 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 0 Participants | 2 Participants |
| Age, Continuous | 62.6 years | 76.8 years | 69.7 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 1 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 1 Participants | 4 Participants |
| Region of Enrollment United States | 3 participants | 1 participants | 4 participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Male | 1 Participants | 1 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 3 | 0 / 1 |
| other Total, other adverse events | 3 / 3 | 1 / 1 |
| serious Total, serious adverse events | 1 / 3 | 0 / 1 |
Outcome results
Primary
Overall Response Rate (ORR)
Overall response rate (ORR) is reported as the sum of the rates of participants achieving complete remission (CR), partial remission (PR), & clinical improvement (CI). A clinical response is a response with duration of ≥ 12 weeks. CR is defined as all 4 criteria: * No presence of compact neoplastic mast cell aggregates * Serum tryptase level \< 20 ng/mL * Peripheral blood count remission defined as absolute neutrophil count (ANC) ≥1 x 10e9/L + normal differential, Hb ≥11 g/dL, & platelet count ≥100x10e9/L * Complete resolution of palpable hepatosplenomegaly & all biopsy-proven or suspected SM-related organ damage PR is defined as all 3 criteria with response duration ≥12 weeks, that is not CR or progressive disease: * ≥ 50% reduction in neoplastic mast cells * Serum tryptase level reduced ≥50% * Resolution of 1+ biopsy-proven or suspected systemic mastocytosis (SM)-related organ damage findings CI is defined as any improvement in any of the above measures.
Time frame: Up to 6 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Ibrutinib 420 mg/Day | Overall Response Rate (ORR) | 0 Participants |
| Ibrutinib 560 mg/Day | Overall Response Rate (ORR) | 0 Participants |
Secondary
Change in Quality of Life (QoL)
The quality of life (QoL) component of the Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF) modified for mast cell symptoms, a scale of life quality ranking from 0 (best) to 10 (worst), was assessed at baseline and after 1 cycle of ibrutinib treatment (30 days), and reported as the median change in score with standard deviation.
Time frame: 30 days
Population: Results were analyzed for all participants.
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| Ibrutinib 420 mg/Day | Change in Quality of Life (QoL) | Cycle 1 Day (baseline) | 7.0 score on a scale | Standard Deviation 1 |
| Ibrutinib 420 mg/Day | Change in Quality of Life (QoL) | Cycle 2 Day 1 | 7.0 score on a scale | Standard Deviation 2.6 |
| Ibrutinib 560 mg/Day | Change in Quality of Life (QoL) | Cycle 1 Day (baseline) | 6.0 score on a scale | — |
| Ibrutinib 560 mg/Day | Change in Quality of Life (QoL) | Cycle 2 Day 1 | 5.0 score on a scale | — |
Secondary
Change of Mast Cell Burden
The change in the number of neoplastic mast cells in tissues (blood and/or bone marrow), ie, a measure of mast cell burden, will be assessed by immunophenotyping and/or immunohistochemistry (depending on patient and disease specifics) using mast cell markers, eg, CD25, CD30, CD117, tryptase, reticulin, Wright-Giemsa staining, and/or hematoxylin-eosin staining, in peripheral blood smears or bone marrow samples. For each participant, the data are used to collectively determine a single assessment for the number of mast cells present at baseline and after treatment. The outcome is reported as the median change in that level of mast cells, with full range, from baseline up to 2 years.
Time frame: 2 years
Population: The result was only calculated for those participants for whom a post-treatment mast cell level could be determined.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ibrutinib 420 mg/Day | Change of Mast Cell Burden | 47 Percent reduction of mast cells |
| Ibrutinib 560 mg/Day | Change of Mast Cell Burden | 0 Percent reduction of mast cells |
Secondary
Duration of Response (DoR)
Duration of response (DoR) was assessed through 2 years of treatment, and reported as the median with standard deviation, with response duration censored at last response assessment in the event of death or progression not documented.
Time frame: 2 years
Population: No participants achieved clinical response per protocol (minimum of any clinical improvement ≥ 12 weeks). On that basis, the overall duration of that response can not be determined.
Secondary
Ibrutinib Pharmacokinetics (PK)
Plasma concentration-time profiles for each subject and mean plasma concentration-time profiles for each dose level will be plotted, plasma concentration data for ibrutinib at each time point will be summarized by descriptive statistics, and PK parameters such as maximum concentration (Cmax), minimum concentration, time at which the Cmax is reached, and area under the curve will be summarized with mean, geometric mean, medium, minimum, maximum, standard deviation, and coefficient of variation.
Time frame: 28 days
Population: Because this study terminated with low total accrual, the funding sponsor elected not to analyze the samples for ibrutinib levels. There are no pharmacokinetics values on which to conduct the outcome analysis.
Secondary
Number of Participants With Adverse Events
Adverse events will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, and reported as the number and percentage of participants having any adverse event; by each grade of adverse event; and by affected body systems.
Time frame: 30 days
Population: All study participants are included in this analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Adverse event | 3 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Grade 1 Adverse Event (mild) | 3 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Grade 2 Adverse Event (moderate) | 3 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Grade 3 Adverse Event (severe) | 2 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Grade 4 Adverse Event (life-threatening) | 0 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Grade 5 Adverse Event (death) | 1 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Blood or Lymphatic System Disorder | 1 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Gastrointestinal Disorder | 1 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any General Disorder | 3 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Infection or Infestation | 2 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Investigations | 1 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Metabolism or Nutrition Disorder | 1 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Musculoskeletal or Connective Tissue Disorder | 1 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Nervous System Disorder | 1 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Skin or Subcutaneous Tissue Disorder | 2 Participants |
| Ibrutinib 420 mg/Day | Number of Participants With Adverse Events | Any Vascular Disorder | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Vascular Disorder | 0 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Adverse event | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any General Disorder | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Grade 1 Adverse Event (mild) | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Musculoskeletal or Connective Tissue Disorder | 0 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Grade 2 Adverse Event (moderate) | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Infection or Infestation | 0 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Grade 3 Adverse Event (severe) | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Skin or Subcutaneous Tissue Disorder | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Grade 4 Adverse Event (life-threatening) | 0 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Investigations | 0 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Grade 5 Adverse Event (death) | 0 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Nervous System Disorder | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Blood or Lymphatic System Disorder | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Metabolism or Nutrition Disorder | 1 Participants |
| Ibrutinib 560 mg/Day | Number of Participants With Adverse Events | Any Gastrointestinal Disorder | 1 Participants |
Secondary
Overall Survival (OS)
Overall survival (OS) was assessed through 2 years of treatment, and recorded as the time from the start of treatment to either progression or death, with values censored at the last response assessment if the participant did not progress or die during that period. OS is reported as reported as the median with standard deviation.
Time frame: 26 months
Population: The single patient receiving ibrutinib 560 mg/day was censored per protocol.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Ibrutinib 420 mg/Day | Overall Survival (OS) | 16.0 months |
Secondary
Progression-free Survival (PFS)
Participants were assessed for progression-free survival (PFS) from the start of treatment through 2 years of treatment. The outcome is reported as the number of participants who were alive without disease progression after 2 years of treatment.
Time frame: 2 years
Population: Results were analyzed for all participants. Values were censored at the last assessment if the participant was lost-to-follow-up or otherwise did not have a 2-year assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Ibrutinib 420 mg/Day | Progression-free Survival (PFS) | 0 Participants |
| Ibrutinib 560 mg/Day | Progression-free Survival (PFS) | 0 Participants |
Secondary
Serum Tryptase Levels
Serum tryptase level is a surrogate marker for the desired histopathologic response, ie, reduction in mast cell burden. Serum tryptase levels are reported as the median of the percent reduction, with full range, from baseline up to 2 years.
Time frame: 2 years
Population: Results were determined for all participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ibrutinib 420 mg/Day | Serum Tryptase Levels | 30 Percent reduction serum tryptase level |
| Ibrutinib 560 mg/Day | Serum Tryptase Levels | 50 Percent reduction serum tryptase level |
Secondary
Time-to-Response (TTR)
Time-to-response (TTR) was assessed through 2 years of treatment, and reported as the median with standard deviation, censored at last response assessment in the event of death or progression not documented.
Time frame: 2 years
Population: No participants achieved clinical response per protocol (minimum of any clinical improvement ≥ 12 weeks). On that basis, the time to achieve per-protocol clinical response can not be determined.
Secondary
Total Symptom Score (TSS)
The totality of systemic mastocytosis was assessed by the total symptom score as measured by a Myeloproliferative Neoplasm Symptom Assessment Form modified for mast cell disorders \[MPN-SAF (MCD)\], and reported as the change in median score with standard deviation at baseline and 30 days. The MPN-SAF is a single, 27-question questionnaire that scores the following general measures on a scale of 0 (best) to 10 (worst): fatigue levels, effects of fatigue, satiety, pain, activity, concentration, dizziness, sleep, mood, anxiety, sexual function, itching, flushing, fever, weight loss, respiratory functions, diarrhea, lesions, and allergic reactions (some of these general terms may describe more than 1 assessment). The score on the MPN-SAF is the sum total of all 27 scores, and the range of scores is from a minimum of 0 (best; symptoms for all assessment absent) to a maximum of 270 (worst; score of 10 on all assessments).
Time frame: 30 days
Population: Results were analyzed for all participants.
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| Ibrutinib 420 mg/Day | Total Symptom Score (TSS) | Cycle 1 Day ( baseline) | 56.0 score on a scale | Standard Deviation 22.1 |
| Ibrutinib 420 mg/Day | Total Symptom Score (TSS) | Cycle 2 Day 1 | 36.0 score on a scale | Standard Deviation 15 |
| Ibrutinib 560 mg/Day | Total Symptom Score (TSS) | Cycle 1 Day ( baseline) | 41 score on a scale | — |
| Ibrutinib 560 mg/Day | Total Symptom Score (TSS) | Cycle 2 Day 1 | 41 score on a scale | — |